Evaluation of chimeric antigen receptor T cell therapy in non-human primates infected with SHIV or SIV.

ABSTRACT: Achieving a functional cure is an important goal in the development of HIV therapy. Eliciting HIV-specific cellular immune responses has not been sufficient to achieve durable removal of HIV-infected cells due to the restriction on effective immune responses by mutation and establishment of latent reservoirs. Chimeric antigen receptor (CAR) T cells are an avenue to potentially develop more potent redirected cellular responses against infected T cells. We developed and tested a range of HIV- and SIV-specific chimeric antigen receptor (CAR) T cell reagents based on Env-binding proteins. In general, SHIV/SIV CAR T cells showed potent viral suppression in vitro, and adding additional CAR molecules in the same transduction resulted in more potent viral suppression than single CAR transduction.

SUBMITTER: Iwamoto N 

PROVIDER: S-EPMC7984852 | biostudies-literature | 2021

REPOSITORIES: biostudies-literature